EPM Overview, Foxwatch Equine Nutrition Hub

What EPM is

EPM is a neurological disease caused by a microscopic parasite (most commonly Sarcocystis neurona, occasionally Neospora hughesi) that gets into the horse's brain or spinal cord and damages the nerves. The parasite's natural lifecycle goes through opossums, who shed it in their feces, contaminating hay, water troughs, and grain bins.

The result is a horse that does not move quite right. The classic presentation is asymmetric: the horse stumbles or drags one hind leg more than the other. Muscle wasting on one side. Difficulty backing up. Sometimes head tilt or facial-nerve weakness. Symptoms come on gradually over weeks or months and can wax and wane.

What EPM is not

This is the most important section. Many things look like EPM at first, and getting the diagnosis right matters because the treatment and prognosis are different[12]. Common look-alikes:

Cervical Vertebral Compressive Myelopathy (CVCM, "wobbler syndrome"): Compression of the spinal cord in the neck. Often symmetric. Confirmed by neck radiographs and myelogram.
EHV-1 Equine Herpesvirus Myeloencephalopathy: Sudden onset, often with fever, often during outbreaks. Confirmed by PCR.
Equine Degenerative Myeloencephalopathy (EDM/eNAD): Vitamin E-responsive degenerative condition, mostly in young horses.
Lyme disease: Tick-borne, can cause neurological signs in some cases.
PSSM masquerade: A horse with severe muscle disease can present as if it were neurological because severe muscle pain limits movement and creates abnormal gait. Get a CK level before chasing the EPM diagnosis[21].

How EPM is diagnosed

The frustrating answer is that it is not as simple as a single blood test. Up to 80% of horses in the eastern US have been exposed to S. neurona at some point[12], so a positive blood antibody test only means "your horse has met the parasite," not "your horse has the disease right now."

The current best practice is to compare antibody concentrations in blood and cerebrospinal fluid (CSF) to calculate a serum:CSF ratio. A low ratio (more antibody in CSF than blood would predict) suggests active CNS infection. Combined with a thorough neurological exam (Mayhew grading), MRI when available, and ruling out the differentials above, this gets you to a diagnosis you can treat with confidence.

Treatment, in plain terms

FDA-approved drugs (ponazuril, diclazuril, sulfadiazine/pyrimethamine) kill the parasite. The course is typically 28-30 days. Most horses improve significantly; full recovery is common but not universal, and improvement after treatment ends is gradual over weeks to months.

What matters as much as the drug: supportive care. Vitamin E supplementation at high doses is standard during treatment because the antioxidant demand on damaged neural tissue is elevated[11]. Anti-inflammatory support, careful exercise progression, and rehabilitation nutrition are all part of the protocol.

Information only, not veterinary medical advice. EPM is a complex diagnosis. If you suspect your horse has neurological signs, contact your veterinarian today. Time matters; earlier treatment generally produces better outcomes.

Operational protocol during EPM treatment

Once a horse begins FDA-approved treatment for EPM, the barn-management protocol changes for the duration:

Vitamin E: 5,000-10,000 IU/day during active treatment, dropping to maintenance (~2,000 IU/day) during rehabilitation[11]. Use natural d-alpha-tocopherol when budget allows; synthetic forms work but require slightly higher doses.
Anti-inflammatory: NSAIDs as directed by attending vet, often pulsed during the most acute phase.
Forage: Free-choice good-quality forage; the horse may eat less during initial treatment, so palatability matters.
Concentrate: Adjust energy density downward if the horse is on stall rest; upward as work resumes during rehab.
Hand-walking: Daily, on flat surfaces, building up to controlled exercise. Do not return to ridden work until vet approves.
Stall environment: Sealed feed bins, secured hay storage, no openings opossums can use. Vector control is part of the management protocol.

Rehabilitation nutrition (post-treatment)

Once acute treatment ends, the horse may have lost significant muscle mass and have impaired neuromuscular coordination. Rehab nutrition focuses on rebuilding muscle without provoking metabolic stress:

Quality protein: 12-14% crude protein with attention to amino acid profile (lysine, threonine, methionine prioritized)[22].
Continued antioxidant support: Vitamin E maintenance dose, selenium, and consideration of CoQ10 for ongoing mitochondrial recovery.
Gradually escalating exercise: Hand-walking, then in-hand work, then under saddle. Track performance with consistent metrics (ridden work tolerance, gait symmetry).
Body condition monitoring: Aim to recover body condition gradually; rapid refeeding can stress the recovering horse.

Co-occurring with PSSM

It is possible (though not common) for a horse to have both PSSM and EPM[21]. The combined management requires reconciling two different sets of dietary priorities: low-NSC for PSSM and adequate calorie density for EPM rehab. Lit_review_21 walks through the integrated protocol.

Diagnostic algorithm

Per lit_review_12_epm_diagnostic_algorithm, the recommended sequence:

Neurological exam with Mayhew grading. Establish symmetry, severity (0-5), and lesion localization (cerebrum, brainstem, cervical spinal cord, thoracolumbar spinal cord).
Differential rule-out. Cervical radiographs +/- myelogram for CVCM. PCR for EHV-1 if recent exposure. Lyme titer in endemic regions. Vitamin E level for EDM/eNAD. CK/AST for PSSM masquerade.
Serology. SAG-1, SAG-5, SAG-6 ELISA on serum for S. neurona. IFAT or ELISA for N. hughesi.
CSF antibody index. If serum positive, paired CSF for serum:CSF ratio. Ratio <100 suggests active CNS infection[12].
Imaging. MRI when available; cervical/cranial focus. Inflammatory lesions, asymmetric T2 signal.

Treatment options

Drug	Class	Course	Notes
Ponazuril (Marquis)	Triazine	28 days, 5 mg/kg PO	FDA-approved. First-line in many practices.
Diclazuril (Protazil)	Triazine	28 days, 1 mg/kg PO	FDA-approved. Pelleted, palatable.
Sulfadiazine + Pyrimethamine (ReBalance)	Folate inhibitor	120-180 days	FDA-approved. Long course, monitor for anemia.

Adjunct vitamin E at 5,000-10,000 IU/day during treatment, with selenium status verified. Anti-inflammatory therapy as clinically indicated. See lit_review_27_inflammation_neurologic_epm for the inflammation-and-injury mechanism review.

Prognosis and outcomes

Per lit_review_30_longterm_outcomes_qol, full neurological recovery occurs in approximately 60-70% of treated cases; partial recovery sufficient for return to lower-intensity work in another 15-20%; persistent deficits requiring retirement in the remaining 10-25%. Predictors of poor outcome: high initial Mayhew grade (4-5), delayed treatment initiation (>30 days from symptom onset), and concurrent metabolic disease.

Relapse rates are 10-20% within the first year. Continued vitamin E supplementation and stress management during the first 6 months post-treatment are associated with reduced relapse, though the evidence is observational.

Equine Protozoal Myeloencephalitis (EPM)